Broad Institute

OCTOBER 11, 2023

The drugs work by blocking a protein, PD-1 — which helps keep immune responses in check — and stimulating the immune system to attack tumors. The team studied the immune response to CRISPR and designed a new technology that they published in 2021 — a way of removing immune-triggering molecules from CRISPR-edited cells.

Research 137

Research Immune Response Clinical Trials Therapies 137

Drug Target Review

JANUARY 15, 2024

Unlike almost every other cell type (except B cells), T cells do not have the exact same chromosomal DNA sequences as other cells in the body. To be therapeutically useful, antigenic peptides must be presented in a way that allows immune responses to destroy cancer cells without causing unacceptable damage to healthy tissue.

Engineering 110

Engineering DNA Virus Immune Response 110

Codon

FEBRUARY 13, 2024

Such contaminants could have the same toxic effects as the bacterial infection, or provoke a severe immune response in the patient, and therefore the phage mixtures must go through extensive purification and testing procedures. This process would begin by taking a sample of bacteria from the patient and sequencing its DNA.

Therapies 134

Therapies Virus DNA Clinical Trials 134

PLOS: DNA Science

SEPTEMBER 5, 2024

Targeted cancer drugs developed to treat one type of cancer often expand, with further testing, to treat other types, based on molecular similarities. This removes the cancer’s blocking of the immune response, so that T cells can fight the cancer. More information enables more treatment choices.

Treatment 70

Treatment FDA Approval DNA Small Molecule 70

DrugBank

FEBRUARY 26, 2025

These strategies represent a shift in how antibiotics are discovered, developed, and deployed. Targeting Novel Bacterial Pathways Traditional antibiotics often target essential bacterial processes such as cell wall synthesis or DNA replication. AMPs disrupt bacterial membranes, making them less susceptible to resistance development.

Therapies 52

Therapies Pharmaceutical Companies Pharmacokinetics Treatment 52

The Pharma Data

NOVEMBER 29, 2020

Compared to placebo, participants vaccinated with three HB-101 doses had: a 48 percent reduction in CMV viremia (presence of CMV DNA in the blood); a 42 percent reduction in the use of antiviral therapy; and. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system.

Vaccine 40

Vaccine Clinical Trials Disease Therapies 40

Codon

SEPTEMBER 29, 2024

mRNA was the intermediate stage between DNA and protein, a dynamic entity that shifted depending on the second-to-second needs of the cell, able to point out if a cell was cancerous or stressed, what kind of cell it was, and so on. It wasn’t a silver bullet to the hard problem of drug development, but it wasn’t too far off either.

Engineering 143

Engineering Virus DNA Therapies 143

Drug Target Review

DECEMBER 13, 2024

Engineering sites on the antibody to enable specific and consistent attachment of the cytotoxic drug to achieve an optimal drug-to-antibody ratio (DAR). Innovations in payload substances, such as topoisomerase inhibitors (topo-1i), and next-generation DNA- damaging agents to replace older, more toxic agents. 2024;347:122676.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

Drug Target Review

DECEMBER 11, 2024

Unlocking this potential requires a dual approach: Identifying suitable targets within tumours and developing effective biomarkers for patient stratification. Discovering and optimising potent therapeutics that direct the immune response against these targets.

Immune Response 52

Immune Response Engineering Therapies Small Molecule 52

Codon

NOVEMBER 3, 2024

As an undergraduate biology student, I spent some time in a TB lab working on antibiotic resistance — a growing concern for drug developers. Some fluoroquinolones — a class of antibiotics that inhibits DNA replication — may even cause psychosis. tuberculosis. However, hope prevails.

Vaccine 106

Vaccine Trials Therapies Treatment 106